Increased efficacy of human natural interferon alpha (IFN-alpha n3) versus human recombinant IFN-alpha 2 for inhibition of HIV-1 replication in primary human monocytes - PubMed
Comparative Study
. 1993 Nov;9(11):1115-22.
doi: 10.1089/aid.1993.9.1115.
Affiliations
- PMID: 8312053
- DOI: 10.1089/aid.1993.9.1115
Comparative Study
Increased efficacy of human natural interferon alpha (IFN-alpha n3) versus human recombinant IFN-alpha 2 for inhibition of HIV-1 replication in primary human monocytes
S X Fan et al. AIDS Res Hum Retroviruses. 1993 Nov.
Abstract
Natural IFN-alpha n3, a purified mixture of many different natural IFN alpha species, was 10- to 100-fold more effective than equal concentrations of human rIFN-alpha 2b or rIFN-alpha 2a for inhibition of HIV replication in primary human monocytes. This difference was highly reproducible in multiple side-by-side experiments using the identical HIV-1 inoculum and the same monocyte target cells: natural IFN-alpha n3 was more effective than rIFN-alpha 2b at lower concentrations for protection against a constant HIV-1 inoculum; cells treated with natural IFN-alpha n3 were protected against a greater HIV-1 challenge than were cells treated with the same concentration of rIFN-alpha 2b. Fractionation of natural IFN-alpha n3 by reversed-phase high-pressure liquid chromatography (RP-HPLC) showed that most antiviral activity for HIV localized to discrete and reproducible peaks. The RP-HPLC peak that contained purified natural IFN-alpha 2b was the least effective fraction. These data suggest heterogeneity among IFN-alpha species for antiviral activity against HIV and may provide a molecular basis for more effective IFN-alpha therapy.
Similar articles
-
Zhao XX, Hua J, Smith T, Ferencz-Biro K, Liao MJ, Rashidbaigi A. Zhao XX, et al. Hum Antibodies. 1997;8(3):129-36. Hum Antibodies. 1997. PMID: 9322083
-
Fan SX, Turpin JA, Aronovitz JR, Meltzer MS. Fan SX, et al. J Leukoc Biol. 1994 Sep;56(3):362-8. doi: 10.1002/jlb.56.3.362. J Leukoc Biol. 1994. PMID: 8083609
-
Gendelman HE, Baca LM, Kubrak CA, Genis P, Burrous S, Friedman RM, Jacobs D, Meltzer MS. Gendelman HE, et al. J Immunol. 1992 Jan 15;148(2):422-9. J Immunol. 1992. PMID: 1729362
-
Crance JM, Deloince R, Leveque F, Jouan A, Trépo C. Crance JM, et al. C R Acad Sci III. 1994 Jan;317(1):94-7. C R Acad Sci III. 1994. PMID: 7987698 French.
Cited by
-
Strayer DR, Carter WA, Stouch BC, Stittelaar KJ, Thoolen RJ, Osterhaus AD, Mitchell WM. Strayer DR, et al. Antiviral Res. 2014 Oct;110:175-80. doi: 10.1016/j.antiviral.2014.07.010. Epub 2014 Aug 9. Antiviral Res. 2014. PMID: 25111905 Free PMC article.
-
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.
Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, Cheng VC, Tsui WH, Hung IF, Lee TS, Guan Y, Peiris JS, Yuen KY. Chen F, et al. J Clin Virol. 2004 Sep;31(1):69-75. doi: 10.1016/j.jcv.2004.03.003. J Clin Virol. 2004. PMID: 15288617 Free PMC article.
-
Hottiger MO, Felzien LK, Nabel GJ. Hottiger MO, et al. EMBO J. 1998 Jun 1;17(11):3124-34. doi: 10.1093/emboj/17.11.3124. EMBO J. 1998. PMID: 9606194 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources